BN Business News
Add your company to Business Communicator →

Business · 16/11/20261 min read

Fortvita Receives Its First Positive CHMP Opinion, Recommending Zybrivo® (sintilimab) for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer

EDITORIAL ILLUSTRATIONBBusinessBN
Illustration generated by Business News; it is not a source photograph.

Summary

The opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is Fortvita's first European regulatory milestone; if approved, Zybrivo would expand first-line treatment options for eligible patients with lung cancer in Europe PALO ALTO, Calif., Nov....

Original source language: PR Newswire UK — News ReleasesOpen original release →

Explore insights

Business insights →